Back to top

Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials

Plus Therapeutics (PSTV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Plus Therapeutics, Inc. (PSTV)